Enhancing Clonal Outgrowth: Optimal Strategies with InstiGRO® CHO PLUS

The demand for protein therapeutics has soared since their introduction, driving the need for improved production methods which ensure both higher capacity and consistent product quality. Chinese Hamster Ovary (CHO) cell lines are often the mammalian cell line of choice due to their rapid growth, and ability to express foreign proteins, which result in high product yields. Unfortunately, the development of stable cell lines for manufacturing of protein therapeutics can be a significant challenge due to the numerous cell culture bottlenecks. Should the metabolic needs of the cells not be met following single cell isolation, clonal outgrowth can be very low. This amounts to increased project expenditure and timelines for both Contract Development Manufacture Organisations (CDMOs), such as UGA Biopharma, and independent pharmaceutical companies.